Canopy Growth (CGC) names a new CFO

: CGC | Canopy Growth Corporation  News, Ratings, and Charts

CGC – Canadian marijuana manufacturer Canopy Growth appoints former Constellation Brands’ senior executive Mike Lee as the company’s acting chief financial officer.

Canadian marijuana manufacturer and related products provider Canopy Growth (CGC – Get Report) on Tuesday said it has appointed former Constellation Brands’ (STZ – Get Report) senior executive Mike Lee as the company’s acting chief financial officer.

Smiths Falls, Ontario-based Canopy Growth said Lee will take on the role of acting finance chief effective June 1. He will become permanent chief financial officer upon receiving Health Canada security clearance required for all officers and directors, the company said.

Lee was previously senior vice president and CFO of Constellation Brands’ wine and spirits division. Most recently, Lee served in the role of executive vice president, finance at Canopy Growth.

Current CFO Tim Saunders will continue to serve as a strategic adviser in areas of mergers and acquisitions, corporate financing, and business transformation, the company said.

Shares of Canopy Growth were up 2.22% at $44.23 in early trading in New York. Constellation Brands shares were up 0.6% at $204.27.

Canopy Growth is a diversified cannabis, hemp and cannabis device maker and distributor, offering brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through the company’s subsidiary, Storz & Bickel GMbH & Co. KG.

It operates retail stores across Canada under the Tweed and Tokyo Smoke banners. Canopy Growth also trades on the Toronto Stock Exchange under the symbol “WEED.”


Canopy Growth Corp. shares were trading at $44.79 per share on Tuesday afternoon, up $1.52 (+3.51%). Year-to-date, Canopy Growth Corporation (CGC - Get Rating) has gained 66.69%, versus a 15.10% rise in the benchmark S&P 500 index during the same period.

Canopy Growth Corporation (CGC - Get Rating) currently has a POWR Rating of C (Neutral), and is ranked #42 of 202 stocks in the Medical – Pharmaceuticals category.


This article is brought to you courtesy of TheStreet.

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Top Stories on

: hexo | HEXO Corp. Common Shares News, Ratings, and Charts

Why this analyst just rated shares of HEXO a “buy”

Yesterday MKM Partners analyst Bill Kirk initiated coverage of Hexo Corp. (HEXO) with a "buy" rating.
NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

What is the Worst Case Scenario for Stocks?

We need to consider just how bad things would get for the S&P (SPY) if the China deal fell apart. Yes, other indices would likely take it even harder. Let's review how this would likely unfold and our trading strategies.
: CGC | Canopy Growth Corporation  News, Ratings, and Charts

What's next for Canopy Growth (CGC), as Bruce Linton finally moves on

For the world's largest cannabis company by market cap, Canopy Growth (CGC) has seen its fair share of shake-ups in the past few months.
NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

What Quadruple Witching Friday Means for Investors

A bigger factor in the dampening of the witching effect is the explosion of new products and expansion of expirations offered. Continue reading to see what quadruple witching Friday means for investors.
NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

Repo Market Chaos Could Lead to a Crisis

Chaos in short-term funding markets this week forced the Federal Reserve to step in with a series of overnight rescue operations. Continue reading for more details.

Read More Stories

More Canopy Growth Corporation (CGC) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CGC News
Page generated in 1.6864 seconds.